MCID: AGG011
MIFTS: 22

Aggressive B-Cell Non-Hodgkin Lymphoma

Categories: Blood diseases, Immune diseases, Rare diseases

Aliases & Classifications for Aggressive B-Cell Non-Hodgkin Lymphoma

MalaCards integrated aliases for Aggressive B-Cell Non-Hodgkin Lymphoma:

Name: Aggressive B-Cell Non-Hodgkin Lymphoma 58
Aggressive B-Cell Nhl 58

Characteristics:

Orphanet epidemiological data:

58

Classifications:

Orphanet: 58  
Rare haematological diseases


External Ids:

Orphanet 58 ORPHA300846

Summaries for Aggressive B-Cell Non-Hodgkin Lymphoma

MalaCards based summary : Aggressive B-Cell Non-Hodgkin Lymphoma, also known as aggressive b-cell nhl, is related to lymphoma, hodgkin, classic and lymphoma, non-hodgkin, familial. An important gene associated with Aggressive B-Cell Non-Hodgkin Lymphoma is HSPH1 (Heat Shock Protein Family H (Hsp110) Member 1). The drugs Pixantrone and Gemcitabine have been mentioned in the context of this disorder. Affiliated tissues include b cells, t cells and bone.

Related Diseases for Aggressive B-Cell Non-Hodgkin Lymphoma

Diseases related to Aggressive B-Cell Non-Hodgkin Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 17)
# Related Disease Score Top Affiliating Genes
1 lymphoma, hodgkin, classic 11.0
2 lymphoma, non-hodgkin, familial 11.0
3 b-cell non-hodgkin lymphoma 11.0
4 b-cell lymphoma 10.8
5 diffuse large b-cell lymphoma 10.7
6 lymphoma 10.7
7 neutropenia 10.7
8 follicular lymphoma 10.6
9 mantle cell lymphoma 10.4
10 burkitt lymphoma 10.3
11 relapsed/refractory diffuse large b-cell lymphoma 10.2
12 primary mediastinal b-cell lymphoma 10.2
13 peripheral nervous system disease 10.2
14 severe combined immunodeficiency 10.2
15 neuropathy 10.2
16 pulmonary embolism 10.2
17 acute graft versus host disease 10.2

Graphical network of the top 20 diseases related to Aggressive B-Cell Non-Hodgkin Lymphoma:



Diseases related to Aggressive B-Cell Non-Hodgkin Lymphoma

Symptoms & Phenotypes for Aggressive B-Cell Non-Hodgkin Lymphoma

Drugs & Therapeutics for Aggressive B-Cell Non-Hodgkin Lymphoma

Drugs for Aggressive B-Cell Non-Hodgkin Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pixantrone Approved, Investigational Phase 3 144510-96-3
2
Gemcitabine Approved Phase 3 95058-81-4 60750
3
Sargramostim Approved, Investigational Phase 3 123774-72-1, 83869-56-1
4
Allopurinol Approved Phase 3 315-30-0 2094
5
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
6
Bleomycin Approved, Investigational Phase 3 11056-06-7 5360373
7
Fludarabine Approved Phase 3 21679-14-1, 75607-67-9 30751
8
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
9
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
10
Lenalidomide Approved Phase 3 191732-72-6 216326
11
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
12
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
13
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
14
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
15
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
16
leucovorin Approved Phase 3 58-05-9 6006 143
17
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
18
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
19
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
20 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
21
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
22
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
23
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
25
Prednisolone hemisuccinate Experimental Phase 3 2920-86-7
26 Free Radical Scavengers Phase 3
27 Antioxidants Phase 3
28 Calcium, Dietary Phase 3
29 Protective Agents Phase 3
30 Antimetabolites Phase 3
31 Immunosuppressive Agents Phase 3
32 Anti-Infective Agents Phase 3
33 Antiviral Agents Phase 3
34 Bendamustine Hydrochloride Phase 3
35 Anti-Bacterial Agents Phase 3
36 Antibiotics, Antitubercular Phase 3
37 Hormone Antagonists Phase 3
38 Antimitotic Agents Phase 3
39
Liposomal doxorubicin Phase 3 31703
40 Antineoplastic Agents, Hormonal Phase 3
41 Anti-Inflammatory Agents Phase 3
42 glucocorticoids Phase 3
43 Hormones Phase 3
44 Antiemetics Phase 3
45 Folic Acid Antagonists Phase 3
46 Gastrointestinal Agents Phase 3
47 Dermatologic Agents Phase 3
48 Folate Phase 3
49 Vitamin B9 Phase 3
50 Autonomic Agents Phase 3

Interventional clinical trials:

(show all 24)
# Name Status NCT ID Phase Drugs
1 A Randomized Multicenter Study Comparing Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma Who Have Relapsed After Therapy With CHOP-R or an Equivalent Regimen and Are Ineligible for Stem Cell Transplant Completed NCT01321541 Phase 3 Pixantrone + Rituximab;Gemcitabine + Rituximab
2 A Phase III Randomized Trial of Low-Dose Versus Standard-Dose mBACOD Chemotherapy With rGM-CSF for Treatment of AIDS-Associated Non-Hodgkin's Lymphoma Completed NCT00000658 Phase 3 Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Allopurinol;Methotrexate;Cytarabine;Leucovorin calcium;Sargramostim;Dexamethasone
3 Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA) Recruiting NCT03570892 Phase 3 Tisagenlecleucel after optional bridging and lymphodepleting chemotherapy;Platinum-based immunochemotherapy followed in responding patients with high dose chemotherapy and autologous hematopoietic stem cell transplant (HSCT)
4 B-NHL 2013 - Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents Recruiting NCT03206671 Phase 3 Rituximab window;Additional doses of Rituximab;Cyclophosphamide;Cytarabine;Dexamethasone;Doxorubicin hydrochloride;Vindesine Sulfate;Etoposide;Ifosfamide;Methotrexate;Prednisolone;Vincristine
5 Phase II Study for Treatment of Patients With Relapsed or Primary Refractory Aggressive B- Cell NHL and Anthracycline Chemotherapy Pretreatment, Who Received or Did Not Qualify for Autologous Stem Cell Transplantation. Unknown status NCT00385125 Phase 2 Bendamustine;Rituximab
6 Randomized Phase II Study About the Application of Pegfilgrastim (Neulasta) at Day 2 or Day 4 Within the Treatment in Patients With Aggressive Non-Hodgkin's Lymphoma Aged 61 to 80 Years With 6 or 8 Cycles of Chemotherapy With CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) at 14-day Intervals (CHOP-14), Both With or Without the Monoclonal Anti-CD20 Antibody Rituximab Completed NCT00726700 Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
7 National, Open-label, Multicentre Phase I-II Study of Combination R-ESHAP With Lenalidomide as Salvage Therapy for Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Candidates to Stem-cell Transplantation Completed NCT02340936 Phase 1, Phase 2 LR-ESHAP (lenalidomide 5 mg);LR-ESHAP (lenalidomide 10 mg);LR-ESHAP (lenalidomide 15 mg);LR-ESHAP (lenalidomide 20 mg)
8 A Phase 2 Study of Lisocabtagene Maraleucel (JCAR017) as Second-Line Therapy in Adult Patients With Aggressive B-cell NHL (017006) Recruiting NCT03483103 Phase 2
9 A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies Recruiting NCT03484702 Phase 2 JCAR017
10 A Phase II Study of Nivolumab in Combination With DA-REPOCH Followed by Short Course Nivolumab Consolidation in Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma Recruiting NCT03749018 Phase 2 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Prednisone;Vincristine Sulfate
11 A Safety Trial of Lisocabtagene Maraleucel (JCAR017) for Relapsed and Refractory (R/R) B-cell Non-Hodgkin Lymphoma (NHL) in the Outpatient Setting Recruiting NCT03744676 Phase 2
12 A Phase II Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Bendamustine and Rituximab (BR) for Patients With Relapsed/Refractory Aggressive B Cell Lymphomas Recruiting NCT02747732 Phase 2 Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6
13 An Exploratory Phase 1/2 Trial To Evaluate The Safety And Efficacy Of JCAR017 Combinations In Subjects With Relapsed/Refractory B-Cell Malignancies (PLATFORM) Recruiting NCT03310619 Phase 1, Phase 2 Durvalumab;CC-122
14 Phase II Trial of Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma Recruiting NCT04094142 Phase 2 Acalabrutinib
15 A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas Recruiting NCT03038672 Phase 2 Varlilumab
16 A Phase 2/3 Multi-center Study to Evaluate the Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory Aggressive B-Cell Non Hodgkin Lymphoma Active, not recruiting NCT02910063 Phase 2 Blinatumomab
17 A Phase II Study of Mabthera (Rituximab) in Children and Adolescents With Relapsed and Refractory B-Cell NHL/L3ALL Terminated NCT00180895 Phase 2 Rituximab
18 A Two-Stage Phase 1 Open-Label Study of huJCAR014, CD19-Targeted Chimeric Antigen Receptor (CAR)-Modified T Cells Bearing a Human Binding Domain, in Adult Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Acute Lymphocytic Leukemia Recruiting NCT03103971 Phase 1 Cyclophosphamide;Fludarabine
19 Phase I/Ib Clinical Trial of Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells in Adults With Recurrent or Refractory B Cell Malignancies Recruiting NCT04088890 Phase 1 Fludarabine;Cyclophosphamide;CD22 CAR
20 A Phase I Trial of High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma Active, not recruiting NCT01840566 Phase 1 Carmustine;Etoposide;Cytarabine;Melphalan
21 A Phase 1, Open-label, Dose-escalation Study of SGN-CD19B in Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Terminated NCT02702141 Phase 1 SGN-CD19B
22 (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell NHL Terminated NCT01300793 Phase 1 Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide
23 Retrospective Collection of Data on Patient With Relapsed/Refractory Aggressive Non Hodgkin Lymphoma Treated With Y90 Ibritumomab Tiuxetan Radioimmunotherapy Plus High-Dose Chemotherapy and Autologous Stem Cell Transplant Completed NCT02992223
24 DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas Recruiting NCT02633111

Search NIH Clinical Center for Aggressive B-Cell Non-Hodgkin Lymphoma

Genetic Tests for Aggressive B-Cell Non-Hodgkin Lymphoma

Anatomical Context for Aggressive B-Cell Non-Hodgkin Lymphoma

MalaCards organs/tissues related to Aggressive B-Cell Non-Hodgkin Lymphoma:

40
B Cells, T Cells, Bone, Bone Marrow, Spleen

Publications for Aggressive B-Cell Non-Hodgkin Lymphoma

Articles related to Aggressive B-Cell Non-Hodgkin Lymphoma:

(show top 50) (show all 143)
# Title Authors PMID Year
1
Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. 61
31868632 2020
2
Antiproliferative and proapoptotic effects of Inula viscosa extract on Burkitt lymphoma cell line. 61
32013807 2020
3
Outcomes in patients with aggressive B-cell non-Hodgkin lymphoma after intensive frontline treatment failure. 61
31568564 2020
4
Efficacy and safety of pixantrone for the treatment of multiply relapsed or refractory aggressive non-Hodgkin B-cell lymphomas. 61
31997425 2020
5
Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306). 61
31879945 2020
6
Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. 61
31446199 2019
7
Upfront autologous hematopoietic stem cell transplantation consolidation for patients with aggressive B-cell lymphomas in first remission in the rituximab era: A systematic review and meta-analysis. 61
31441943 2019
8
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products. 61
31342797 2019
9
Primary Dural Diffuse Large B-cell Lymphoma: A Comprehensive Review of Survival and Treatment Outcomes. 61
31902733 2019
10
Pixantrone beyond monotherapy: a review. 61
31312929 2019
11
Rituximab and reduced-intensity chemotherapy in children and adolescents with mature B-cell lymphoma: interim results for 231 patients enrolled in the second Russian-Belorussian multicentre study B-NHL-2010M. 61
31069789 2019
12
Recent advances and future directions in mantle cell lymphoma research: report of the 2018 mantle cell lymphoma consortium workshop. 61
30696305 2019
13
Intussusception in children: lessons learned from intestinal lymphoma as a rare lead-point. 61
31139892 2019
14
Burkitt lymphoma presenting with fever of unknown origin and isolated hypoglossal nerve palsy. 61
31425376 2019
15
The acceleration of CAR-T therapy in non-Hodgkin lymphoma. 61
30427551 2019
16
CD19 CAR T cells following autologous transplantation in poor-risk relapsed and refractory B-cell non-Hodgkin lymphoma. 61
31262783 2019
17
Treatment of aggressive B-cell non-Hodgkin lymphoma beyond frontline therapy in patients not eligible for stem cell transplantation: a structured review. 61
30702000 2019
18
The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. 61
30782611 2019
19
Review of Bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma. 61
31043832 2019
20
Bilateral mantle cell lymphoma of the ciliary body that responded to a combined local radiotherapy and chemotherapy regimen: a case report. 61
30987612 2019
21
Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma. 61
30919158 2019
22
CD19 Chimeric Antigen Receptor Therapy for Refractory Aggressive B-Cell Lymphoma. 61
30557517 2019
23
The rationale for combination therapy in patients with aggressive B-cell non-Hodgkin lymphoma: ten questions. 61
30280924 2019
24
Management of adults with Burkitt lymphoma. 61
30843890 2018
25
Phase I Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma. 61
30166257 2018
26
High-grade Burkitt Lymphoma Presenting as a Buttock Mass and Foot Drop. 61
30510878 2018
27
Low rate of spleen involvement in sporadic Burkitt lymphoma at staging on PET-CT. 61
29460043 2018
28
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. 61
28677896 2018
29
Impact of salvage treatment modalities in patients with positive FDG-PET/CT after R-CHOP chemotherapy for aggressive B-cell non-Hodgkin lymphoma. 61
29577608 2018
30
Pre-clinical activity of targeting the PI3K/Akt/mTOR pathway in Burkitt lymphoma. 61
29774105 2018
31
Does maintenance therapy have a role in mantle cell lymphoma treatment? 61
29521148 2018
32
Outcomes after Allogeneic Stem Cell Transplantation in Patients with Double-Hit and Double-Expressor Lymphoma. 61
29196080 2018
33
Triptolide induces mitochondria-mediated apoptosis of Burkitt's lymphoma cell via deacetylation of GSK-3β by increased SIRT3 expression. 61
29407771 2018
34
Burkitt's lymphoma with placental invasion diagnosed at cesarean delivery: a case report. 61
29415774 2018
35
Assessment of CD52 expression in "double-hit" and "double-expressor" lymphomas: Implications for clinical trial eligibility. 61
30020951 2018
36
The Role of Macrophage/B-Cell Interactions in the Pathophysiology of B-Cell Lymphomas. 61
29868471 2018
37
Clinical characteristics and survival outcome of primary effusion lymphoma: A review of 105 patients. 61
27859456 2017
38
Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy. 61
28870643 2017
39
Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. 61
29222274 2017
40
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. 61
28485023 2017
41
Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop. 61
28140709 2017
42
L-PROBe: A Novel Non-anthracycline Combination Chemotherapy Regimen for Aggressive B Cell Non-Hodgkin Lymphoma in Elderly Patients. 61
28194058 2017
43
Consolidation radiotherapy for advanced-stage aggressive B-cell non-Hodgkin lymphoma: A systematic review and meta-analysis. 61
29285019 2017
44
Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review. 61
28321348 2017
45
Unusual multiple metastatic localisations in adult Burkitt's lymphoma. A case report. 61
27981287 2016
46
Pixantrone: A Review in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma. 61
27757832 2016
47
Impact of Fc gamma-receptor polymorphisms on the response to rituximab treatment in children and adolescents with mature B cell lymphoma/leukemia. 61
27376362 2016
48
Monotherapy with pixantrone in histologically confirmed relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: post-hoc analyses from a phase III trial. 61
27118109 2016
49
A multicenter phase II study of sepantronium bromide (YM155) plus rituximab in patients with relapsed aggressive B-cell Non-Hodgkin lymphoma. 61
26857688 2016
50
Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma. 61
27093976 2016

Variations for Aggressive B-Cell Non-Hodgkin Lymphoma

Expression for Aggressive B-Cell Non-Hodgkin Lymphoma

Search GEO for disease gene expression data for Aggressive B-Cell Non-Hodgkin Lymphoma.

Pathways for Aggressive B-Cell Non-Hodgkin Lymphoma

GO Terms for Aggressive B-Cell Non-Hodgkin Lymphoma

Sources for Aggressive B-Cell Non-Hodgkin Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....